SLC39A13

protein-coding

solute carrier family 39 member 13, the group of Solute carrier family 39

Gene summary

This gene encodes a member of the LIV-1 subfamily of the ZIP transporter family. The encoded transmembrane protein functions as a zinc transporter. Mutations in this gene have been associated with the spondylocheiro dysplastic form of Ehlers-Danlos syndrome. Alternate transcript variants have been found for this gene. [provided by RefSeq, Jan 2016]

MANE transcript

NM_001128225.3

Inheritance

AR

ClinVar variants

P:4U:137B:135

Top phenotype

Ehlers-Danlos syndrome, spondylodysplastic type, 3

gnomAD constraint

pLI —, LoF o/e 0.43

Max pathogenic AF

—

Genomic locus

chr11:47,407,132-47,416,496

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~9.4 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

Ehlers-Danlos syndrome, spondylodysplastic type, 3DEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: ClinGen

The SLC39A13 gene encodes the zinc transporter 13 (ZIP13), which facilitates the transport of zinc from the Golgi apparatus to the cytosol, thereby regulating cellular zinc homeostasis. The gene was first linked to rare early-onset autosomal recessive spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS) in 2008 by two separate groups (Giunta et al., PMID: 18513683 and Fukada et al., PMID: 18985159). In addition to common EDS symptoms such as thin, soft, velvety skin and hypermobile joints, affected individuals exhibit short stature, platyspondyly, tapering fingers, clubfoot, osteopenia, and abnormal radiological findings, including irregular vertebral endplates, flattened epiphyses, enlarged metaphysis, and short, broad femoral necks. Common craniofacial dysmorphic features are protruding eyes, blue sclera, and downslanting palpebral fissures. Other phenotypes are delayed eruption of permanent teeth or oligodontia, wrinkled palm skin, and thenar atrophy. Some patients were also reported muscle weakness, gait disturbances, and corneal abnormalities, with variability between and within families. Six unique homozygous variants, including three missense, one nonsense, one recurrent small deletion, and one splicing variant, have been identified in fourteen patients from eight families across five publications (PMIDs: 18513683, 18985159, 29593477, 32295219, 36727144). The case-level data from these eight probands provide 7.7 points for genetic evidence. The pathogenic mechanism is loss-of-function, supported by experimental evidence. Phenotypes observed in null knockout (KO) mouse model align with symptoms in affected individuals (PMID: 18985159). Studies on osteoblasts, odontoblasts, and dermal fibroblasts from wildtype and KO mice indicate that ZIP13 is crucial for zinc homeostasis and connective tissue development via the BMP/TGF-beta/SMAD signaling pathway (PMID: 18985159). The amount of endogenous ZIP13 protein in patient dermal fibroblasts was significantly reduced compared to cells derived from a heterozygous parent, and zinc failed to be transported into the cytosolic region (PMID: 23213233). In vitro overexpression of the p.Gly74Asp or p.Phe162_Ala164del variants in 239T or Hela cells results in unstable ZIP13 proteins undergoing VCP-dependent degradation (PMID: 25007800). Additionally, ZIP13 transcript is upregulated by myogenic stimulation in C2C12 mouse myoblasts and human dermal fibroblasts, along with the upregulation of myogenic regulatory factors MyoD and Myogenin. Knockdown of ZIP13 expression impairs myogenic differentiation, as evidenced by undifferentiated cell morphology and decreased MYH expression. In patient-derived stem cells with the p.Gly74Asp variant, MyoD, Myogenin, and MYH mRNA and protein levels are reduced compared to healthy controls. Correcting the p.Gly74Asp variant from homozygous to heterozygous state in patient stem cells using gene editing rescues Myogenin mRNA and protein expression after eight days, suggesting ZIP13's role in myogenic differentiation (PMID: 38609428). In summary, SLC39A13 is definitively associated with autosomal recessive SCD-EDS, as demonstrated in both clinical diagnostic and research settings, and has been upheld over time. This classification was approved by the ClinGen IEM GCEP on October 25th, 2024. (SOP Version 11).

Ehlers-Danlos syndrome, spondylodysplastic type, 3STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: PanelApp Australia

Ehlers-Danlos syndrome, spondylodysplastic type, 3STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: Genomics England PanelApp

Ehlers-Danlos syndrome, spondylodysplastic type, 3STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: Labcorp Genetics (formerly Invitae)

Ehlers-Danlos syndrome, spondylodysplastic type, 3DEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: G2P

Ehlers-Danlos syndrome, spondylodysplastic type, 3LIMITED

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: Ambry Genetics

Ehlers-Danlos syndrome, spondylodysplastic type, 3SUPPORTIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012873

Submitter: Orphanet

Clinical Genomic Database (CGD)

Ehlers-Danlos syndrome, spondylodysplastic type, 3AR

Manifestation: Craniofacial; Dermatologic; Musculoskeletal

Intervention: General

Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing

Refs: 18985159; 18513683Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to SLC39A13 variants in ClinVar

14 Conditions Cataloged
Ehlers-Danlos syndrome, spondylodysplastic type, 3Total: 299
not providedTotal: 106
not specifiedTotal: 88
Inborn genetic diseasesTotal: 54
SLC39A13-related disorderTotal: 20
Ehlers-Danlos syndromeTotal: 14
Connective tissue disorderTotal: 8
Mitral valve prolapseTotal: 1

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001128225.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
4
clinvar
117
clinvar
121
missense
2
clinvar
127
clinvar
17
clinvar
1
clinvar
147
nonsense
2
clinvar
2
clinvar
4
start loss
0
frameshift
2
clinvar
2
splice donor/acceptor (+/-2bp)
2
clinvar
2
Total041371341276

Highest pathogenic variant AF is 0.000009307128

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 97 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001128225.3RefSeqNP_001121697.29MANE Select
ENST00000362021.9EnsemblENSP00000354689.49MANE Select
NM_001330245.2RefSeqNP_001317174.28Standard
NM_001441271.1RefSeqNP_001428200.19Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Nuclear Receptors Meta-Pathway
  • NRF2 pathway
  • Zinc homeostasis

Biological Process

  • cellular zinc ion homeostasis
  • response to zinc ion
  • connective tissue development
  • zinc ion transmembrane transport

Molecular Function

  • zinc ion transmembrane transporter activity
  • protein binding
  • protein homodimerization activity

Cellular Component

  • endoplasmic reticulum
  • Golgi apparatus
  • integral component of membrane
  • integral component of Golgi membrane
  • perinuclear region of cytoplasm

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000362021
Coding exons
9
Length
9365
Individuals with no LoFs
125707
Homozygous LoFs
0
Heterozygous LoFs
29
Defined
125736
p
0.000115
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense1.261702230.7630.00001462347
Missense (PolyPhen)4874.6570.64294851
Synonymous-0.2751081041.030.00000768819
Loss of Function2.16716.40.4268.04e-7181

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000250.00025rare
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian0.000220.00022rare
Finnish00.0absent
European (Non-Finnish)0.000140.00014rare
South Asian0.000130.00013rare
Other0.000170.00016rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Acts as a zinc-influx transporter. {ECO:0000269|PubMed:21917916}.;
Disease
DISEASE: Ehlers-Danlos syndrome, spondylodysplastic type, 3 (EDSSPD3) [MIM:612350]: A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSSPD3 is an autosomal recessive form characterized by a generalized skeletal dysplasia involving mainly the spine and striking clinical abnormalities of the hands, in addition to classic features of Ehlers-Danlos syndrome. Clinical features include postnatal growth retardation, moderate short stature, protuberant eyes with bluish sclerae, hands with finely wrinkled palms, atrophy of the thenar muscles, and tapering fingers. Radiologic features include mild to moderate platyspondyly, mild to moderate osteopenia of the spine, small ileum, flat proximal femoral epiphyses, short, wide femoral necks, and broad metaphyses (elbows, knees, wrists, and interphalangeal joints). {ECO:0000269|PubMed:18513683}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.124

Intolerance Scores

LoFtool
0.656
RVIS EVS
0.98
RVIS percentile EVS
90.38

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
S
Essential (gene trap)
N
Indispensability pred.
N
Indispensability score
0.485

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.